ATLASALPS Medical Breakthroughs ETF (SBIO): outlook, holdings and fees
ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund and is managed by ALPS. The expense ratio is 0.49% and the yield is 0.00%. The ten largest holdings are 30% of the fund.
Fund data as of Oct 14, 2026 · Price Nov 2, 2026
ATLAS view on SBIO
| Last price | $53.73 (-2.1%) |
|---|---|
| ATLAS chance of a higher price in 1 month | 50% |
| Likely 1-month range (50%) | $50.55 – $57.17 |
| Normal 1-day range (±1σ) | ±2.1% |
| Distribution yield | 0.00% |
ATLAS probabilities use the same calibrated model as every stock page. A fair value is shown for companies, not funds; the holdings below link to the fair value of each company.
SBIO fund facts
| Issuer | ALPS |
|---|---|
| Theme | Healthcare |
| Assets under management | $197M |
| Expense ratio | 0.49% |
| Number of holdings | 50 |
| Portfolio turnover | 83% |
| Inception | Dec 30, 2014 |
| Exchange | NYSE |
The fund employs a passive management - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
SBIO top holdings
| Holding | Sector | Weight |
|---|---|---|
| CG Oncology, Inc. Common stock CGON | Healthcare | 3.58% |
| Veradermics, Incorporated MANE | Healthcare | 3.51% |
| Oruka Therapeutics, Inc. ORKA | Healthcare | 3.44% |
| Definium Therapeutics, Inc. DFTX | Healthcare | 3.26% |
| Travere Therapeutics Inc TVTX | Healthcare | 3.14% |
| Dianthus Therapeutics Inc. DNTH | Healthcare | 3.06% |
| Edgewise Therapeutics Inc EWTX | Healthcare | 2.95% |
| Relay Therapeutics Inc RLAY | Healthcare | 2.53% |
| Amylyx Pharmaceuticals Inc AMLX | Healthcare | 2.39% |
| Xenon Pharmaceuticals Inc XENE | Healthcare | 2.26% |
Holdings with an ATLAS page link to their probability range, fair value and earnings calendar.
SBIO sector breakdown
| Sector | Weight |
|---|---|
| Healthcare | 100.0% |
By region: North America 94.0%, Europe Developed 2.3%, Asia Emerging 2.0%, United Kingdom 1.8%.
SBIO returns and risk
| Year to date | +9.6% |
|---|---|
| 1 year | +40.6% |
| 3 years (annualised) | +30.7% |
| 5 years (annualised) | +5.5% |
| 10 years (annualised) | +8.5% |
| Volatility (3 years) | 28.2% |
| Sharpe ratio (3 years) | 0.92 |
Past returns do not guarantee future results.
SBIO: frequently asked questions
What does SBIO invest in?
ALPS Medical Breakthroughs ETF invests in a portfolio of securities. Its largest holdings are CG Oncology, Inc. Common stock (3.6%), Veradermics, Incorporated (3.5%), Oruka Therapeutics, Inc. (3.4%), Definium Therapeutics, Inc. (3.3%), Travere Therapeutics Inc (3.1%).
What is the SBIO expense ratio?
0.49% a year: about $49.00 for every $10,000 invested.
What is the SBIO dividend yield?
0.00%. ATLAS does not hold the exact distribution dates for ETFs.
Will SBIO go up?
Nobody can know. The ATLAS model puts the chance of a higher price in one month at 50%, with a likely range (50%) of $50.55 to $57.17 from $53.73 today. It is a probability, not a prediction.
How has SBIO performed?
Year to date +9.6%, one year +40.6%, three years +30.7% a year, five years +5.5% a year. Past returns do not guarantee future results.
Similar ETFs: Healthcare
- State Street Health Care Select Sector SPDR ETF (XLV)
- Vanguard Health Care ETF (VHT)
- iShares Global Healthcare ETF (IXJ)
- iShares U.S. Healthcare ETF (IYH)
- iShares U.S. Medical Devices ETF (IHI)
- Fidelity MSCI Health Care Index ETF (FHLC)
- iShares U.S. Pharmaceuticals ETF (IHE)
- First Trust Health Care AlphaDEX Fund (FXH)
Educational information, not investment advice. Disclaimer